公开(公告)号：US20180319819A1

公开(公告)日：2018-11-08

申请号：US15769201

申请日：2016-10-21

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Takatoshi YOGO ,  Masato YOSHIKAWA ,  Morihisa SAITOH ,  Taisuke KATOH ,  Tomohiro SEKI ,  Yoshihisa NAKADA

IPC: C07D519/00 ,  A61P25/00

CPC classification number: C07D519/00 ,  A61K31/55 ,  A61K31/553 ,  A61K31/554 ,  A61P1/16 ,  A61P13/12 ,  A61P25/00 ,  A61P31/12 ,  C07D471/04 ,  C07D487/04 ,  C07D513/04

Abstract: The present invention provides a heterocyclic compound having an RIP1 kinase inhibitory action, which is useful for the prophylaxis or treatment of Gaucher's disease, Niemann-Pick disease, inflammatory bowel disease, multiple sclerosis, chronic kidney disease, acute kidney injury, acute hepatic failure, autoimmune hepatitis, hepatitis B, hepatitis C, alcohol steatohepatitis, non-alcohol steatohepatitis and the like.The present invention relates to a compound represented by the following formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US20240390508A1

公开(公告)日：2024-11-28

申请号：US18685457

申请日：2022-08-19

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takatoshi YOGO ,  Hideyuki SUGIYAMA ,  Kenichi MIYATA ,  Hiroyuki TAKADA ,  Masato YOSHIDA ,  Ryosuke TOKUNOH ,  Yasuo NAKAGAWA ,  Masato NIWA ,  Shigekazu SASAKI ,  Masaki OHUCHI ,  Naoki SAWAI ,  Masatoshi TAKUWA ,  Yujiro UCHINO ,  Yoko KANEMATSU ,  Koichiro FUKUDA ,  Takanori YOKOTO ,  Tetsuya NAGATA ,  Hiroki YAMADA

IPC: A61K47/64 ,  A61K38/17 ,  A61K48/00 ,  C12N15/113

Abstract: The present invention aims to provide a novel drug delivery system (DDS) technique capable of selectively delivering a drug (compound containing oligonucleotides for producing at least partially functional dystrophin protein) to muscle tissues such as cardiac muscle, skeletal muscle and the like and efficiently introducing the drug into the muscle cells. The present invention relates to a conjugate or a salt thereof including the following: (1) a peptide that binds to a transferrin receptor, and contains the amino acid sequence shown in SEQ ID NO: 1 (Ala-Val-Phe-Val-Trp-Asn-Tyr-Tyr-Ile-Ile-Ser-Cys); or an amino acid sequence resulting from substitution, deletion, addition, and/or insertion of not less than one and not more than 10 amino acid residues in the amino acid sequence shown in SEQ ID NO: 1, and (2) a compound comprising an oligonucleotide for producing an at least partially functional dystrophin protein.

公开(公告)号：US20170174682A1

公开(公告)日：2017-06-22

申请号：US15452003

申请日：2017-03-07

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masato YOSHIDA ,  Hiroyuki NAGAMIYA ,  Yusuke OHBA ,  Masaki SETO ,  Takatoshi YOGO ,  Satoshi SASAKI ,  Norihito TOKUNAGA ,  Kazuyoshi ASO

IPC: C07D471/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  C07D519/00

Abstract: Provided is a compound or a salt thereof, which has an excellent JAK inhibitory action, and is useful as a prophylactic or therapeutic agent for autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's syndrome, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like. The present invention relates to a compound represented by the formula (I) wherein each symbol is as defined in the present specification, or a salt thereof.